Work

Abstract PS1-11-10: Real-world progression-free survival 2 (rwPFS2) and tumor response with CDK4/6is + aromatase inhibitor (AI) in patients (pts) with HR+/HER2- metastatic breast cancer (MBC)

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps1-11-10

Authors: H. S. Rugo, A. Brufsky, R. M. Layman, X. Liu, B. Li, L. McRoy, A. B. Cohen, M. Estevez, P. Cottu, M. Thill, G. Curigliano

Institutions: City Of Hope National Medical Center, City of Hope, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, The University of Texas MD Anderson Cancer Center, Pfizer (United States), Flatiron Health (United States), Université Paris Cité, Agaplesion Markus Hospital, University of Milan, European Institute of Oncology

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129677834

Cites:

Cited by:

Related to: